Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

Swiss stocks - Factors to watch on June 8

Published 08/06/2016, 03:22 pm
Updated 08/06/2016, 03:30 pm
© Reuters.  Swiss stocks - Factors to watch on June 8

ZURICH, June 8 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Wednesday:

SWISS PRIVATE BANKS

A British exit from the European Union could push the world's wealthy to keep less of their cash in London and turn to Swiss private banks instead, the chairman of Boston Consulting Group's (BCG) Swiss office said.

SOON.S

A rival of the Swiss hearing aid maker, Denmark's William Demant WDH.CO , is seeking to buy more retail outlets to control sales of its products and fight discounters including Costco (NASDAQ:COST). Sonova sells its products to Costco, but has also been buying up retail outlets to replace rivals' products on the shelves with its own. more click SOON.S

COMPANY STATEMENTS CPR-CH

* VimpelCom (NASDAQ:VIP) and CK Hutchison Holdings have received preliminary bids for some of their assets from Swisscom SCMN.S , Iliad SA and Digicel Group, Bloomberg reported, citing people familiar with the matter. SCMN.S

* Swiss Prime Site SPSN.S said it successfully completed a 250 million Swiss franc convertible bond issue due 2023. SPSN.S

* NAGRA, a Kudelski KUD.S company, and NOS Comunicações SA, announced the launch of a 4K Ultra HD RDK-enabled set-top box offering secured by NAGRA anyCAST CONNECT. KUD.S

*Schaffner SAHN.S said its aiming to have an EBITA margin of better than 8 percent while returning to growth over the next two years. SAHN.S

* Implenia AG IMPN.S said it is building a new mixed-use, sustainable neighbourhood at "Werk 1" on Sulzerareal site in central Winterthur, where housing is slated to be built on property that once formed the heart of Swiss industry. IMPN.S

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

* Roche ROG.S said it received EU approval for Avastin, Tarceva combination in a specific kind of lung cancer. ROG.S

* Novartis NOVN.S said it is presenting information about its Cosentyx medication for psoriatic arthritis and ankylosing spondolytis at a conference. The Swiss drugmaker is counting on the drug to help make up for the patent expiration of its blood cancer medicine Gleevec. NOVN.S

ECONOMY M-CH

* CPI CHCPIY=ECI data due at 0715 GMT

* Result of the Swiss federal bond issue SWIW due around 0900 GMT

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.